Associated Papers
Genotype and clinical phenotype characteristics of MAX germline mutation-associated pheochromocytoma/paraganglioma syndrome.
Lian B et al.
Frontiers in Endocrinology, 2024
Bilateral Pheochromocytoma with Germline MAX Variant without Family History.
Hata S et al.
Clinics and Practice, 2022
35645312 (PubMed )
Supplement: clinpract-12-00035-s001.zip › clinpract-1702561-supplementary.pdf
Temozolomide treatment of a malignant pheochromocytoma and an unresectable MAX-related paraganglioma.
Ferrara AM et al.
Anti-cancer Drugs, 2018
MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma.
Burnichon N et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2012
Select a paper to view details